Edition:
United States

Inotek Pharmaceuticals Corp (ITEK.OQ)

ITEK.OQ on NASDAQ Stock Exchange Global Market

2.31USD
13 Dec 2017
Change (% chg)

-- (--)
Prev Close
$2.31
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
215,249
52-wk High
$7.40
52-wk Low
$0.85

Chart for

About

Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower... (more)
No analyst recommendations are available for .

Overall

Beta: --
Market Cap(Mil.): $62.88
Shares Outstanding(Mil.): 27.22
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 188.50 15.25
EPS (TTM): -- -- --
ROI: -- -11.67 33.27
ROE: -- -36.21 16.35

BRIEF-Inotek files for preliminary proxy statement for proposed merger with Rocket Pharmaceuticals

* Inotek Pharmaceuticals announces filing of preliminary proxy statement for proposed merger with clinical-stage gene therapy company, Rocket Pharmaceuticals

Oct 12 2017

BRIEF-‍Adage Capital Partners reports 5.55 pct stake in Inotek Pharmaceuticals

* ‍Adage Capital Partners reports 5.55 percent stake in Inotek Pharmaceuticals as of September 26 - SEC filing​

Oct 05 2017

BRIEF-Braden Leonard reports 5.6 pct passive stake in Inotek Pharmaceuticals as of Sept 13 - SEC Filing

* Braden M Leonard reports 5.6 percent passive stake in Inotek Pharmaceuticals Corp as of Sept 13, 2017 - SEC Filing Source text: [http://bit.ly/2xw5tXM] Further company coverage:

Sep 20 2017

BRIEF-Inotek Pharmaceuticals announces merger agreement with Rocket Pharmaceuticals to advance pipeline of first-in-class gene therapies for rare diseases

* Inotek Pharmaceuticals announces merger agreement with Rocket Pharmaceuticals to advance pipeline of first-in-class gene therapies for rare diseases

Sep 12 2017

BRIEF-Inotek Pharmaceuticals qtrly loss per share $0.24

* Inotek Pharmaceuticals Corporation reports second quarter 2017 financial results and operational highlights

Aug 03 2017

Inotek to explore strategic options after eye drug fails trial

Inotek Pharmaceuticals Corp said on Friday it would evaluate strategic options after its sole experimental eye drug failed another trial, sending the company's shares tumbling 45 percent in extended trading.

Jul 07 2017

UPDATE 2-Inotek to explore strategic options after eye drug fails trial

July 7 Inotek Pharmaceuticals Corp said on Friday it would evaluate strategic options after its sole experimental eye drug failed another trial, sending the company's shares tumbling 45 percent in extended trading.

Jul 07 2017

Inotek to consider strategic options after eye drug fails another study

July 7 Inotek Pharmaceuticals Corp said on Friday it would evaluate its lead experimental drug and consider strategic options after the eye drug failed another trial.

Jul 07 2017

BRIEF-Inotek Pharmaceuticals says evaluating strategic alternatives

* Inotek Pharmaceuticals announces top-line results of phase 2 fixed-dose combination trial of trabodenoson and provides corporate update

Jul 07 2017

Earnings vs. Estimates